CV:IPA ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol IPA.

8.48 CAD
As of 06/18/2021

---

Security Information

---

Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Communication Services
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  01/01/1900
Stock exchange:    TSX Venture Exchange
Exchange country:   Canada
Market cap:   0 CAD
Current dividend yield:   0.00%
CUSIP:    
ISIN:        CA45257F1018
Sedol: